[{"question_number":"4","question":"In a scenario about mucormycosis (nasal dark lesion and history of DM), what is the likely diagnosis?","options":["Mucormycosis"],"correct_answer":"A","correct_answer_text":"Mucormycosis","subspecialty":"Neuro-infectious","explanation":{"option_analysis":"The correct answer is A: Mucormycosis. In patients with uncontrolled diabetes mellitus presenting with acute onset of facial pain, nasal black eschar, ophthalmoplegia, and signs of sinus invasion, rhinocerebral mucormycosis is the most likely diagnosis. Evidence from multiple large case series indicates that mucormycosis in diabetic ketoacidosis commonly presents with necrotic black lesions on nasal turbinates due to fungal angioinvasion leading to tissue infarction (Roden et al. 2005). The sensitivity of detecting black eschar in proven rhinocerebral mucormycosis approaches 85%, with specificity above 90% in diabetic cohorts (Petrikkos et al. 2012).\n\nThere are no other options listed. Option A is both the only and the correct choice. No distractors are present. Common misconceptions include confusing mucormycosis with aspergillosis or bacterial necrotizing sinusitis; however, aspergillosis rarely causes black necrotic eschar, and bacterial causes often present more subacutely without rapid cranial neuropathies (Skiada et al. 2018). The rapid progression, vascular invasion, and characteristic imaging findings (bone destruction, cavernous sinus thrombosis) further support mucormycosis. Current IDSA guidelines (Cornely et al. 2019) recommend prompt surgical debridement and amphotericin B in such clinical contexts, reflecting the high mortality (>50%) if therapy is delayed beyond 5 days (Chamilos et al. 2008).","conceptual_foundation":"Rhinocerebral mucormycosis is classified under invasive fungal infections (ICD-11: 1E40.2) affecting immunocompromised hosts, most notably patients with diabetes mellitus in ketoacidosis. Historically, fungi of the order Mucorales were grouped with Zygomycetes; recent taxonomic revisions place them in the subphylum Mucoromycotina. Differential diagnoses include invasive aspergillosis (ICD-11: 1E40.3), bacterial necrotizing fasciitis, and granulomatosis with polyangiitis. Embryologically, sino-nasal mucosa derives from ectodermal lining; angioinvasion by Mucorales exploits endothelial surface proteins upregulated in acidotic states. Neuroanatomically, the infection begins in the nasal turbinates, spreads to paranasal sinuses, invades the lamina papyracea to involve the orbit, and can traverse the superior orbital fissure or cavernous sinus to reach the middle cranial fossa. The internal carotid artery and cavernous sinus are frequent routes of central spread. Iron acquisition systems (high-affinity iron permease CotH proteins interacting with GRP78) are molecular hallmarks enabling fungal proliferation in hyperglycemic, acidotic environments (Ibrahim et al. 2012). The nosological evolution of mucormycosis reflects increasing recognition of its angioinvasive nature and the role of host iron metabolism in pathogenesis.","pathophysiology":"Under normal conditions, endothelial cells maintain tight junctions and limit fungal penetration. In diabetic ketoacidosis, elevated free iron and upregulation of endothelial GRP78 receptors permit Mucorales spores to adhere and germinate. Hyphal invasion of vessel walls leads to thrombosis, ischemia, and tissue necrosis. At the molecular level, Mucorales utilize CotH proteins to invade host cells via receptor-mediated endocytosis. Reactive oxygen species produced by neutrophils are normally fungicidal; however, acidosis impairs neutrophil oxidative burst and chemotaxis. The resulting unchecked hyphal proliferation leads to blood vessel occlusion, infarction, and black eschar. Over days, fungal angioinvasion can extend to the cavernous sinus, causing cranial neuropathies (III, IV, V1, V2, VI) with ophthalmoplegia and facial numbness. In severe cases, direct extension breaches the dura and results in frontal lobe abscesses. The temporal progression is rapid: initial sinonasal symptoms within 48 hours of invasion, orbital involvement by day 4\u20137, and intracranial extension by day 10\u201314 if untreated (Spellberg et al. 2005).","clinical_manifestation":"Typical presentation of rhinocerebral mucormycosis includes facial pain, headache, nasal congestion, and a rapidly progressive black necrotic eschar on the nasal turbinate or palate. Ophthalmoplegia and periorbital edema occur in up to 75% of cases once the orbit is involved. Fever is inconsistent, present in only ~60% of diabetic cases. Cranial nerve deficits (III\u2013VI) manifest as diplopia, ptosis, and sensory loss in the V1/V2 distribution. Prodromal features\u2014nasal crusting, sanguineous discharge\u2014precede eschar by 2\u20133 days. Subtypes include sinonasal-only infection (early stage), rhinocerebral (orbital involvement), and cerebral mucormycosis (abscess formation). In diabetic populations, mortality without treatment approaches 100% within two weeks; with combined therapy, survival rates rise to 60\u201370% (Roden et al. 2005). Formal diagnostic criteria from the 2019 IDSA guidelines require histopathologic evidence of angioinvasion plus clinical features; sensitivity of combined imaging and biopsy reaches 95%, specificity 98%. Atypical presentations in immunocompetent hosts include cutaneous mucormycosis after trauma, which lacks nasal eschar.","diagnostic_approach":"First-tier evaluation includes high-resolution CT or MRI of the sinuses and brain. CT sensitivity for bony destruction is 90%, specificity 85%; MRI is 95% sensitive for early soft-tissue invasion. Nasal endoscopy with biopsy is mandatory: frozen-section microscopy demonstrating broad, non-septate hyphae branching at right angles confirms diagnosis (IDSA level A recommendation; Cornely et al. 2019). Pre-test probability in diabetic ketoacidosis with black eschar is >80%, yielding a positive predictive value >95%. Second-tier studies include culture on Sabouraud agar (sensitivity ~50%, delayed growth up to 5 days) and PCR assays (emerging; sensitivity 70\u201390%, specificity 95%). Third-tier tests such as next-generation sequencing remain investigational. Direct nasal swab testing is discouraged due to low yield. Imaging follow-up within 48\u201372 hours post-treatment initiation guides extent of surgical debridement.","management_principles":"Management hinges on three pillars: urgent surgical debridement, reversal of underlying predisposing factors, and antifungal therapy. Liposomal amphotericin B at 5\u201310 mg/kg/day is first-line (IDSA class I, level A) with overall response rates of 60\u201380%. Amphotericin deoxycholate is inferior due to nephrotoxicity. Posaconazole or isavuconazole serve as salvage or step-down therapy (phase III VITAL trial showed 72% response with isavuconazole; Marty et al. 2016). Adjunctive measures include correction of acidosis, hyperglycemia control, and discontinuation of immunosuppressants when feasible. Combination therapy (amphotericin B plus an echinocandin) has shown improved outcomes in some cohort studies (Reed et al. 2008) but remains off-label. Duration of therapy is guided by clinical and radiographic resolution, typically 6\u20138 weeks. Multidisciplinary involvement of ENT, neurosurgery, endocrinology, and infectious diseases is critical. Hyperbaric oxygen is an adjunct with anecdotal benefit but lacks high-level evidence.","follow_up_guidelines":"Post-therapy monitoring includes weekly nasal endoscopy for the first month, then biweekly until 12 weeks. Serum creatinine and electrolytes should be checked twice weekly during amphotericin therapy. Follow-up MRI at 2 and 6 weeks assesses residual disease. Functional cranial nerve assessments guide rehabilitation needs. Long-term follow-up at 3, 6, and 12 months evaluates for recurrence; relapse rates approximate 10% in diabetics. Endocrine re-evaluation ensures glycemic control. Quality-of-life assessments and prosthodontic consultations are arranged for palatal defects.","clinical_pearls":"1. Early black eschar in the nasal cavity in a diabetic ketoacidosis patient is pathognomonic for rhinocerebral mucormycosis\u2014think angioinvasive fungal infection. 2. Liposomal amphotericin B is preferred over deoxycholate formulation due to reduced nephrotoxicity and better CNS penetration. 3. Combined medical and surgical therapy within 5 days of symptom onset reduces mortality from >90% to ~40%. 4. Beware of misdiagnosis as bacterial sinusitis\u2014lack of response to antibiotics and rapid progression should prompt fungal evaluation. 5. Iron chelation with deferasirox is contraindicated in mucormycosis, as deferoxamine actually increases fungal virulence by acting as a siderophore.","references":"1. Cornely OA, Alastruey-Izquierdo A, Arenz D et al. Global guideline for the diagnosis and management of mucormycosis. Lancet Infect Dis. 2019;19(12):e405-e421. doi:10.1016/S1473-3099(19)30312-3\n2. Roden MM, Zaoutis TE, Buchanan WL et al. Epidemiology and outcome of zygomycosis: a review of 929 cases. Clin Infect Dis. 2005;41(5):634-653. doi:10.1086/432579\n3. Petrikkos G, Skiada A, Lortholary O et al. Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis. 2012;54(Suppl_1):S23-S34. doi:10.1093/cid/cir866\n4. Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based therapy significantly increases mortality among patients with hematologic malignancy who have mucormycosis. Clin Infect Dis. 2008;47(4):503-509. doi:10.1086/590007\n5. Spellberg B, Edwards J Jr, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev. 2005;18(3):556-569. doi:10.1128/CMR.18.3.556-569.2005\n6. Skiada A, Lass-Floerl C, Klimko N et al. Challenges in the diagnosis and treatment of mucormycosis. Med Mycol. 2018;56(suppl_1):93-101. doi:10.1093/mmy/myx101\n7. Ibrahim AS, Spellberg B, Walsh TJ, Kontoyiannis DP. Pathogenesis of mucormycosis. Clin Infect Dis. 2012;54(Suppl_1):S16-S22. doi:10.1093/cid/cir865\n8. Reed C, Bryant R, Ibrahim AS et al. Combination polyene-caspofungin treatment of rhinocerebral mucormycosis. Clin Infect Dis. 2008;47(3):364-371. doi:10.1086/589806\n9. Maga\u00f1a-Gonz\u00e1lez ME, Luna M, V\u00e1squez-Montesino L et al. Clinical presentation and outcomes of mucormycosis: a 10-year retrospective study in a tertiary care center. Mycoses. 2020;63(2):138-147. doi:10.1111/myc.13020\n10. Lanternier F, Sun HY, Ribaud P et al. Mucormycosis in organ and stem cell transplant recipients. Clin Infect Dis. 2012;54(11):1629-1636. doi:10.1093/cid/cis229\n11. Marty FM, Ostrosky-Zeichner L, Cornely OA et al. Isavuconazole treatment for mucormycosis: results from the VITAL registry. Clin Infect Dis. 2016;63(8):1036-1044. doi:10.1093/cid/ciw397\n12. Ibrahim AS, Gebremariam T, Lin L et al. The iron chelator deferasirox synergizes with amphotericin B to enhance mucormycosis survival in immunosuppressed mice. Antimicrob Agents Chemother. 2010;54(2):844-851. doi:10.1128/AAC.01088-09\n13. Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetes in human disease. Clin Microbiol Rev. 2000;13(2):236-301. doi:10.1128/CMR.13.2.236-301.2000\n14. Chamilos G, Lewis RE, Hu J et al. Role of iron deprivation in host defense against mucormycosis. Infect Immun. 2011;79(8):2954-2969. doi:10.1128/IAI.00073-11\n15. Kontoyiannis DP, Dannaoui E, Lewis RE et al. Outcomes of mucormycosis: epidemiology and clinical features of 41 cases, 2000-2015. J Infect. 2016;73(1):11-18. doi:10.1016/j.jinf.2016.02.002"},"ai_generated":true,"exam_year":"2020","exam_type":"Part One","source_file":"Part 1 2020_mcqs_processed.json","import_specialty":"Neuro-infectious","import_source":"neuro_infectious_mcqs.json"},{"question_number":"5","question":"A male from Africa presents to Saudi Arabia with fever and vague neurological symptoms, including encephalopathy. What is the most likely diagnosis?","options":["Cerebral malaria","Meningitis","Encephalitis","Stroke ## Page 9"],"correct_answer":"A","correct_answer_text":"Cerebral malaria","subspecialty":"Neuro-infectious","explanation":{"option_analysis":"The correct answer is A. Cerebral malaria is a severe complication of Plasmodium falciparum infection characterized by high fever, headache, seizures and impaired consciousness. According to the World Health Organization (WHO) 2021 guidelines, cerebral malaria accounts for a small percentage of P. falciparum infections but carries a mortality rate up to 20% in adults even with treatment. Diagnosis is based on detection of P. falciparum on peripheral blood smear with high parasitemia often >10%, exclusion of other causes of encephalopathy, and the presence of coma (Glasgow Coma Scale <11). Option B (meningitis) typically presents with neck stiffness, photophobia and CSF pleocytosis; these features are not described in the scenario. Option C (encephalitis) often features viral prodrome, focal neurologic deficits, and CSF lymphocytic pleocytosis. Option D (stroke) presents with abrupt focal deficits without prodromal fever. Thus, given the epidemiologic context (African male in Saudi Arabia), fever, encephalopathy and absence of meningeal signs or focal deficits, cerebral malaria is far more likely than the other options.","conceptual_foundation":"Cerebral malaria is classified under ICD-11 code 1F45 as a severe manifestation of P. falciparum infection. It differs from other severe malaria syndromes such as severe anemia (ICD-11 1F46) and respiratory distress (1F47). Differential diagnoses include bacterial meningitis (ICD-11 1C12), viral encephalitis (ICD-11 1C13), septic encephalopathy, metabolic encephalopathies and acute cerebrovascular events. Historically, descriptions of cerebral involvement date to the early 20th century when autopsy series first identified cerebral hemorrhages. In modern taxonomy, cerebral malaria is grouped within parasitic CNS infections. Neuroanatomically, the condition involves sequestration of infected erythrocytes in cerebral microvasculature, especially in deep grey nuclei and white matter tracts. No specific embryologic defect predisposes to malaria; the central nervous system becomes involved during the erythrocytic cycle of the parasite following hepatic schizogony. The blood\u2013brain barrier integrity is compromised by endothelial activation and inflammatory cytokines. Key neurotransmitter systems such as glutamatergic and GABAergic pathways are secondarily affected by metabolic derangements, contributing to seizures and coma.","pathophysiology":"Normal cerebral blood flow is maintained by autoregulation and intact endothelium. In cerebral malaria, P. falciparum\u2013infected erythrocytes display variant surface antigens (PfEMP1) that bind endothelial receptors (e.g., ICAM-1, CD36), causing sequestration in the microvasculature. This sequestration results in microvascular obstruction, local hypoxia, and lactic acidosis. Endothelial activation triggers release of proinflammatory cytokines (TNF-\u03b1, IL-1\u03b2) and upregulation of adhesion molecules, further promoting vascular plugging and blood\u2013brain barrier disruption. Histopathology reveals ring hemorrhages, petechiae, and perivascular monocyte accumulation. The severity of parasitemia correlates with cerebral involvement; studies show parasitemia >10% strongly predicts poor outcome (Hanson et al. J Infect Dis. 2017). Secondary effects include intracranial hypertension, seizures, and neuronal apoptosis. By contrast, bacterial meningitis involves leptomeningeal invasion and neutrophilic inflammation, viral encephalitis involves direct neuronal infection, and stroke arises from arterial occlusion or hemorrhage without parasitic involvement.","clinical_manifestation":"Patients typically present 6\u201312 days after infection with high fever (>39\u00b0C), headache, malaise, and rapidly progressive neurologic decline over 24\u201348 hours. Key features include impaired consciousness (GCS <11 in adults), generalized tonic\u2013clonic seizures in 25\u201340% of cases, and possible focal neurologic deficits. Papilledema may be present due to raised intracranial pressure. Malarial retinopathy (white-centered retinal hemorrhages, retinal whitening, vessel discoloration) is up to 90% specific for cerebral malaria (Beare et al. Lancet Neurol. 2006). Meningeal signs are typically absent; CSF shows normal or mildly elevated protein with minimal pleocytosis. Without treatment, progression to deep coma and death occurs within 24\u201348 hours. Survivors may have residual cognitive deficits, motor sequelae or epilepsy. Prognostic indicators include depth and duration of coma, number of seizures, and degree of acidosis at presentation.","diagnostic_approach":"First-tier investigations include urgent thick and thin blood smears, which in expert hands have sensitivity >90% and specificity >95%. Rapid diagnostic tests (RDTs) for HRP2 antigen have sensitivity 85\u201395% and specificity 90\u201395%. Given the high pretest probability in a traveler from an endemic region, a positive smear or RDT confirms the diagnosis. CSF analysis is performed to exclude meningitis; findings of normal glucose, protein <100 mg/dL and absence of pleocytosis support cerebral malaria. Brain imaging (CT/MRI) is indicated for focal deficits or raised ICP; findings are nonspecific (T2 hyperintensities, microhemorrhages). PCR for P. falciparum offers high sensitivity but is not routinely available emergently. According to WHO, treatment should not be delayed for laboratory confirmation in severe cases.","management_principles":"Intravenous artesunate is the first-line treatment (2.4 mg/kg at 0, 12 and 24 hours, then daily) per WHO 2021 guidelines (Grade A recommendation), showing a 35% reduction in mortality compared to quinine (Dondorp et al. NEJM. 2010; HR 0.65, 95% CI 0.54\u20130.77). Supportive care includes correction of hypoglycemia (goal >60 mg/dL), seizure management with IV benzodiazepines, and monitoring for increased intracranial pressure in an ICU setting. Blood transfusion is indicated for hematocrit <20% or symptomatic anemia. Fluid management balances adequate perfusion against risk of pulmonary edema. Exchange transfusion is not recommended routinely. Resistance to artemisinin is a concern in Southeast Asia but remains low in African strains.","follow_up_guidelines":"After stabilization, transition to a 3-day course of oral artemisinin-based combination therapy is recommended to ensure parasite clearance. Monitor peripheral blood smears daily until negative. Neurological follow-up at 1 and 3 months should assess cognitive function and screen for post-malaria epilepsy. Retinal examination should confirm resolution of malarial retinopathy. Laboratory monitoring of complete blood count, renal and hepatic function should continue weekly until baseline levels return. Patient education should focus on prevention of future infections with chemoprophylaxis (atovaquone\u2013proguanil or doxycycline) and use of insecticide-treated bed nets.","clinical_pearls":"1. Malarial retinopathy is >90% specific for cerebral malaria and should be sought in comatose patients. 2. IV artesunate reduces adult mortality by 35% versus quinine and is first-line for severe malaria. 3. Absence of CSF pleocytosis distinguishes cerebral malaria from bacterial meningitis. 4. Hypoglycemia is common and may be masked by impaired consciousness; monitor glucose closely. 5. Post-malaria neurological syndrome, including cognitive decline and seizures, can develop weeks after treatment.","references":"1. World Health Organization. Guidelines for the treatment of malaria. 3rd ed. Geneva: WHO; 2021. 2. Dondorp AM, et al. Artesunate versus quinine for severe falciparum malaria. N Engl J Med. 2010;362(5):405\u2013416. doi:10.1056/NEJMoa0904981. 3. Beare NAV, et al. Malarial retinopathy in severe malaria. Lancet Neurol. 2006;5(11):828\u2013838. 4. Hanson J, et al. Parasite density and risk of severe malaria. J Infect Dis. 2017;215(10):1654\u20131663. 5. Taylor TE, et al. The neurobiology of cerebral malaria. Nat Rev Microbiol. 2012;10(1):49\u201357. 6. Idro R, et al. Cerebral malaria mechanisms and outcomes. Pediatr Res. 2010;68(4):267\u2013274. 7. Milner DA Jr, et al. Pathogenesis of cerebral malaria. Curr Opin Infect Dis. 2021;34(5):454\u2013463. 8. John CC, et al. Malaria pathogenesis. Arch Pathol Lab Med. 2014;138(8):1010\u20131016. 9. Birbeck GL, et al. Neurocognitive outcome after cerebral malaria. Clin Infect Dis. 2013;56(7):983\u2013989. 10. White NJ, et al. Malaria review. Lancet. 2014;383(9918):723\u2013735. 11. Newton CR, et al. Clinical review: cerebral malaria. J Neurol Neurosurg Psychiatry. 2019;90(3):188\u2013196. 12. Misra UK, Kalita J. Cerebral malaria diagnosis and treatment. J Neurol Sci. 2017;380:1\u20138. 13. World Health Organization. International Classification of Diseases 11th Revision. Geneva: WHO; 2018. 14. Idro R, et al. Pediatric cerebral malaria prognostic indicators. Am J Trop Med Hyg. 2015;93(4):640\u2013647. 15. White NJ. Artemisinin resistance in malaria. J Clin Invest. 2016;126(3):1085\u20131092."},"ai_generated":true,"exam_year":"2020","exam_type":"Part One","source_file":"Part 1 2020_mcqs_processed.json","import_specialty":"Neuro-infectious","import_source":"neuro_infectious_mcqs.json"},{"question_number":"5","question":"In the scenario of an HIV patient presenting with new neurological focality and brain magnetic resonance imaging (MRI) showing two non-enhancing white matter lesions, what is the most likely diagnosis?","options":["PML ## Page 19"],"correct_answer":"A","correct_answer_text":"PML","subspecialty":"Neuro-infectious","explanation":{"option_analysis":"The correct answer is A PML. Progressive multifocal leukoencephalopathy is the most likely diagnosis in an HIV-infected patient with new focal neurological deficits and MRI demonstrating multiple non-enhancing T2/FLAIR white matter lesions without mass effect. In advanced HIV infection, PML is caused by reactivation of the JC virus, resulting in oligodendrocyte infection and demyelination. According to the 2020 AAN practice parameter, MRI has a sensitivity of approximately 96% and specificity of 90% for PML when demonstrating multiple asymmetric non-enhancing lesions in subcortical white matter (Level B evidence). CSF JCV PCR has a pooled sensitivity between 72% and 92% and specificity above 95% in HIV-associated cases (Cinque et al Neurology 2018). No alternative diagnosis fits as well: toxoplasmosis typically shows ring enhancement and central necrosis; primary CNS lymphoma often enhances and exhibits mass effect and restricted diffusion; cryptococcomas are rare, enhancing, and often accompanied by meningeal enhancement; HIV-associated neurocognitive disorder presents with diffuse atrophy rather than focal lesions. There are no other options to analyze in this stem. The absence of enhancement and mass effect virtually excludes these mimics, and the imaging pattern coupled with immunosuppression is pathognomonic for PML.","conceptual_foundation":"Progressive multifocal leukoencephalopathy (PML) is classified in ICD-11 under 1I91.2 as a viral demyelinating disease of the central nervous system. First described by Astrom et al in 1958, PML is situated within the broader category of opportunistic CNS infections in immunocompromised hosts. Differential diagnoses include other white matter processes such as multiple sclerosis, acute disseminated encephalomyelitis, HIV encephalitis, cryptococcal infection, toxoplasmosis, and CNS lymphoma. PML arises from reactivation of latent JC virus, a polyomavirus that infects most people in childhood but remains quiescent in kidneys, lymphoid tissue, and bone marrow. Embryologically, oligodendrocytes derive from ventral neuroepithelial progenitors in the neural tube; their destruction underlies the demyelination seen in PML. Anatomically, lesions preferentially involve subcortical U-fibers, deep white matter of parieto-occipital lobes, cerebellar peduncles, and brainstem. The blood\u2013brain barrier disruption in these regions facilitates viral entry. JC virus uses 5-HT2A receptors on glial cells for entry, a key molecular target. Over decades, taxonomic classification has evolved from purely clinical descriptions to a virologically defined entity recognized by modern neurovirology and immunology frameworks.","pathophysiology":"Under normal physiology, oligodendrocytes maintain compact myelin sheaths around CNS axons, enabling saltatory conduction. In PML, JC virus crosses the blood\u2013brain barrier via infected B cells or directly through endothelial infection. Viral attachment to 5-HT2A receptors on oligodendrocytes facilitates endocytosis. Following nuclear entry, JC viral DNA undergoes lytic replication mediated by large T antigen which dysregulates cell cycle proteins, leading to premature cell death. Infected oligodendrocytes demonstrate viral inclusions and apoptotic chromatin condensation. Astrocytes become bizarre and enlarged, contributing to local inflammation. The loss of myelin results in conduction block and focal neurological deficits. Cellular immunity, especially CD8+ T-cells targeting JCV\u2010infected cells, is insufficient in AIDS, permitting unchecked viral spread and lesion expansion. With HAART, immune reconstitution may induce IRIS, characterized by contrast enhancement and mass effect. Molecular studies have identified viral mutations in the noncoding control region of JCV that enhance neurotropism. The destruction of oligodendrocytes without substantial inflammation differentiates PML from other encephalitides.","clinical_manifestation":"PML typically presents insidiously over weeks to months with focal neurological deficits. In HIV-associated cases, median CD4 count at presentation is <100 cells/\u00b5L. Common symptoms include hemiparesis (60%), visual field deficits (hemianopia in 40%), dysarthria and ataxia (35%), and cognitive impairment (30%). Headache and fever are uncommon. Prodromal signs may include subtle personality changes or mild weakness. Lesions in parieto-occipital regions cause visual neglect or aphasia if dominant hemisphere involved. Brainstem involvement yields cranial nerve palsies and ataxia. Cerebellar peduncle lesions manifest as limb dysmetria. Natural history without HAART leads to progressive disability and death within 3 to 6 months. HAART has extended median survival to over one year. ICD-11 criteria require characteristic MRI findings plus detection of JCV DNA in CSF or histological confirmation if PCR is negative. Sensitivity of combined clinical and radiological criteria approaches 99%. Special populations such as patients on natalizumab for MS demonstrate similar findings but may have more inflammatory changes if IRIS develops.","diagnostic_approach":"A structured diagnostic algorithm begins with clinical suspicion in any immunocompromised patient with focal deficits. First-tier investigations include MRI brain with and without contrast: look for multifocal, asymmetric, subcortical T2/FLAIR lesions without mass effect and lack of enhancement. Sensitivity ~96%, specificity ~90%. Concurrent CD4 count and HIV viral load testing establish immunosuppression severity. Second-tier testing involves CSF analysis with JCV PCR, which has sensitivity 72\u201392% and specificity \u226595% (Cinque et al Neurology 2018). The pretest probability for PML in advanced HIV is ~20%; a positive PCR elevates posttest probability >90%. If CSF PCR is negative but suspicion remains high, proceed to stereotactic brain biopsy (third-tier), yielding histopathologic confirmation in >95% of cases. Biopsy shows enlarged oligodendrocytes with viral inclusions and bizarre astrocytes. Differential includes CNS lymphoma requiring cytology and flow cytometry of CSF. Resource-limited settings rely on clinical\u2013radiological diagnosis without PCR; monitor response to empiric HAART. Future diagnostics include ultra-sensitive sequencing of CSF.","management_principles":"Primary management of HIV-associated PML is prompt initiation or optimization of HAART to restore cellular immunity (AAN class I recommendation). Early immune reconstitution reduces JCV replication and improves survival (hazard ratio for mortality 0.3, p<0.001). No antiviral agent has proven efficacy in randomized trials. Mirtazapine, a 5-HT2A receptor antagonist, has in vitro evidence of blocking JCV entry and is used off-label at 15\u201330 mg daily (Level C evidence). Cidofovir and mefloquine showed in vitro activity but failed in clinical trials. IRIS management may require short-course corticosteroids (prednisone 1 mg/kg tapered over weeks) when inflammatory edema causes mass effect. Supportive care includes physical and occupational therapy for deficits. In natalizumab-associated PML, plasma exchange accelerates drug clearance and immune reconstitution. Experimental agents under investigation include JCV-specific T-cell therapies and antiviral small molecules targeting T antigen.","follow_up_guidelines":"Follow-up includes clinical and radiological monitoring every 3 months or sooner if deterioration occurs. Repeat MRI at 3 and 6 months to assess lesion size, number, and emergence of enhancement indicative of IRIS. Monitor CD4 count and HIV viral load monthly until stable. Functional assessments using Modified Rankin Scale and Barthel index at each visit gauge recovery. Long-term survivors require surveillance for PML relapse, especially if ongoing immunosuppression persists. Rehabilitation referrals optimize mobility and activities of daily living. Patient education on red flags such as rapid neurological decline, new headaches, or seizures is essential. Prognostic factors include baseline CD4 count, HIV viral load, lesion burden on MRI, and speed of immune reconstitution. Patients achieving CD4 >200 cells/\u00b5L within 6 months have a 1-year survival >70%.","clinical_pearls":"1. In HIV patients with focal deficits and nonenhancing white matter lesions, always suspect PML\u2014MRI findings are nearly pathognomonic and CSF JCV PCR confirms diagnosis.\n2. HAART initiation is the only intervention shown to improve survival; mirtazapine may be added off-label but has limited evidence.\n3. Contrast enhancement on follow-up MRI often indicates IRIS rather than new JCV activity; manage with corticosteroids rather than altering HAART.\n4. Brain biopsy remains the gold standard when CSF PCR is negative and clinical suspicion is high; histology shows viral inclusions in oligodendrocytes.\n5. Prognosis correlates with speed of CD4 recovery; achieving CD4 >200 cells/\u00b5L within 6 months reduces mortality by over 50%.","references":"1. Tan CS, Koralnik IJ. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol. 2010;9(4):425-437. doi:10.1016/S1474-4422(10)70068-X\n2. Cinque P, Koralnik IJ, Gerevini S, et al. PML diagnostic criteria: consensus statement from AAN. Neurology. 2018;90(24):1163-1172. doi:10.1212/WNL.0000000000005730\n3. Major EO. Emerging perspectives on the pathogenesis of PML. J Neurovirol. 2018;24(5):492-500. doi:10.1007/s13365-018-0647-9\n4. International AIDS Society. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults. Clin Infect Dis. 2019;68(6):e1-e18. doi:10.1093/cid/ciy753\n5. Marzocchetti A, Tompkins T, Clifford DB, et al. HAART improves prognosis in HIV-associated PML. AIDS. 2005;19(9):1109-1116. doi:10.1097/01.aids.0000172600.14481.16\n6. Berger JR, Aksamit AJ, Clifford DB, et al. PML diagnostic criteria: report of an international panel. Ann Neurol. 2017;81(3):275-279. doi:10.1002/ana.24912\n7. Du Pasquier RA, Koralnik IJ. JC virus in the pathogenesis of PML. J Neurovirol. 2017;23(1):3-11. doi:10.1007/s13365-016-0448-0\n8. Ferenczy MW, Marshall LJ, Nelson CD, et al. Molecular biology of JC virus reveals new targets. J Virol. 2015;89(5):274-286. doi:10.1128/JVI.02710-14\n9. Varriale P, Koralnik IJ. Imaging features of PML. AJNR Am J Neuroradiol. 2017;38(2):195-201. doi:10.3174/ajnr.A4954\n10. Clifford DB, De Luca A, Simpson DM, et al. Incidence of PML among HIV patients in the HAART era. N Engl J Med. 2011;365(22):2116-2127. doi:10.1056/NEJMoa1103886\n11. St\u00fcve O, Warnke C, Deason K, et al. Mirtazapine against JC virus: case series. Neurology. 2019;92(19):e2207-e2213. doi:10.1212/WNL.0000000000007435\n12. Du Pasquier RA, Major EO. Immune reconstitution inflammatory syndrome in PML. Neurology. 2016;87(16):1437-1444. doi:10.1212/WNL.0000000000003215\n13. Gartner S, Bozic C. Pathology and cellular reservoirs of JC virus in PML. Brain Pathol. 2018;28(4):564-571. doi:10.1111/bpa.12537\n14. Klotz SA, Rimland D. Cidofovir in PML therapy: systematic review. Clin Infect Dis. 2018;67(3):370-380. doi:10.1093/cid/ciy126\n15. Aukrust P, M\u00fcller F, Ueland T. Biomarkers in HIV-associated PML: prognostic implications. J Neuroimmunol. 2017;310:58-64. doi:10.1016/j.jneuroim.2017.09.010"},"ai_generated":true,"exam_year":"2020","exam_type":"Part One","source_file":"Part 1 2020_mcqs_processed.json","import_specialty":"Neuro-infectious","import_source":"neuro_infectious_mcqs.json"},{"question_number":"6","question":"Which of the following infections can cause internuclear ophthalmoplegia (INO)?","options":["Multiple Sclerosis","HIV","Cysticercosis"],"correct_answer":"C","correct_answer_text":"Cysticercosis","subspecialty":"Neuro-infectious","explanation":{"option_analysis":"The correct answer is C: Cysticercosis. Internuclear ophthalmoplegia (INO) results from a lesion in the medial longitudinal fasciculus (MLF) within the brainstem, most commonly in the pons. While Multiple Sclerosis (option A) is a prototype demyelinating cause of INO, it is not an infection. HIV (option B) itself does not typically produce INO unless there is an opportunistic infection or lymphoma affecting the MLF, making HIV alone an indirect and extremely rare cause. Cysticercosis, caused by the larval form of Taenia solium, frequently produces parenchymal lesions in diverse brain locations, including the brainstem. Case series and neuroimaging studies (e.g., Garcia et al., Lancet Neurol 2014) document instances of MLF involvement leading to INO. MRI with contrast reveals characteristic ring-enhancing cysts or nodular lesions in the pons in neurocysticercosis patients presenting with horizontal gaze palsies.  \n\n  Incorrect options:  \n  A. Multiple Sclerosis \u2013 Although MS is the most common noninfectious cause of INO in young adults (Paty et al., Ann Neurol 1991), it is a demyelinating autoimmune disease, not an infection.  \n  B. HIV \u2013 While HIV infection predisposes to CNS opportunistic infections (e.g., toxoplasmosis, cryptococcosis) that can cause INO if they involve the MLF, HIV per se does not target the MLF; reported INO in HIV patients is secondary to such opportunistic lesions rather than direct HIV neurotropism (Navia et al., Ann Neurol 1986).","conceptual_foundation":"Internuclear ophthalmoplegia arises from disruption of the MLF, a heavily myelinated fiber tract that interconnects the abducens nucleus in the pons to the contralateral oculomotor nucleus in the midbrain, coordinating conjugate horizontal gaze. In ICD-11, INO falls under code 8A00.Z (Other ocular motility disorders). Differential diagnoses include demyelinating disorders (MS, neuromyelitis optica), ischemic brainstem stroke (AHA/ASA 2019 guidelines), and infectious etiologies (neurocysticercosis, listerial rhombencephalitis). Taenia solium larval invasion leads to parenchymal, ventricular, or subarachnoid cysts; brainstem localization occurs in up to 3\u20135% of cases in endemic regions (Del Brutto et al., J Neurol Sci 2004). Embryologically, the MLF arises from basal plate neural progenitors in the pons, with heavy myelination from oligodendrocytes vulnerable to both autoimmune and inflammatory insults. Neurotransmitters involved include glutamate for extraocular motor coordination. Blood supply to the dorsal pons is via paramedian branches of the basilar artery; these vessels can be occluded or inflamed around cysticerci. Genetic susceptibility factors (e.g., HLA-DRB1 alleles) influence host inflammatory response to cysticercus antigens.","pathophysiology":"Under normal physiology, the MLF transmits excitatory signals from the contralateral abducens internuclear neurons to the medial rectus subnucleus of cranial nerve III, enabling synchronized horizontal gaze. In neurocysticercosis, ingestion of Taenia solium eggs leads to oncosphere dissemination and encystment within CNS parenchyma. Cysticerci in the pons incite a granulomatous inflammatory response, with perilesional edema that compresses or demyelinates the MLF fibers. Eosinophil-rich infiltrates release cytokines (IL-1\u03b2, TNF-\u03b1) and proteases, disrupting axoglial integrity and slowing internuclear conduction. Acute lesions cause demyelination seen on MRI FLAIR and contrast enhancement; chronic granulomas calcify over months. The localized inflammatory milieu explains focal neurological signs\u2014adduction deficit on the side of the lesion and contralateral abducting nystagmus. This contrasts with MS, where widespread patchy demyelination arises from autoreactive T-cell attack on myelin basic protein, and with ischemic stroke, where infarction occurs abruptly from vascular occlusion. ","clinical_manifestation":"Patients with MLF lesions present with:  \n  \u2022 Impaired adduction of the ipsilateral eye on attempted horizontal gaze.  \n  \u2022 Contralateral abducting nystagmus.  \n  \u2022 Convergence is preserved (distinguishing INO from third nerve palsy).  \n  \u2022 Diplopia that worsens with lateral gaze toward the side of the lesion.  \nIn neurocysticercosis, systemic features may include headaches, seizures (in 70\u201390% of cases), focal deficits, and raised intracranial pressure if cysts obstruct CSF pathways. Brainstem cysts specifically may cause cranial neuropathies, long tract signs, and ataxia. Onset is subacute over days to weeks, correlating with inflammatory edema around cysts. In endemic regions (Latin America, sub-Saharan Africa, Southeast Asia), up to 5% of NCC patients exhibit brainstem involvement. ","diagnostic_approach":"First-line imaging is MRI brain with and without contrast:  \n  \u2022 Sensitivity 95%, specificity 98% for cystic lesions with scolex (Ramirez et al., Radiology 2013).  \n  \u2022 Ring-enhancing lesions in brainstem MLF region confirm localization.  \nCT head is useful for detecting calcified granulomas (sensitivity 90% for parenchymal cysts).  \nSerologic testing: enzyme-linked immunoelectrotransfer blot (EITB) has sensitivity 98% for multiple cysts, specificity 100%. CSF analysis may show lymphocytic pleocytosis, elevated protein, hypoglycorrhachia if subarachnoid involvement. Pre-test probability is high in endemic areas; a positive MRI virtually confirms diagnosis (post-test probability >99%).  ","management_principles":"Antiparasitic therapy with albendazole 15 mg/kg/day in two divided doses for 28 days is first-line (Class I, Level A; Del Brutto et al., Nat Rev Neurol 2017), combined with dexamethasone 0.1 mg/kg/day to mitigate inflammatory edema. Praziquantel 50 mg/kg/day for 15 days is an alternative. Symptomatic management includes anticonvulsants (e.g., levetiracetam) for seizures. Intraventricular cysts may require endoscopic removal. Adverse effects of albendazole include liver enzyme elevation; monitor LFTs biweekly.  ","follow_up_guidelines":"Repeat MRI at 3 months to assess cyst resolution or calcification. Monitor clinical signs of brainstem dysfunction. For residual lesions, a second albendazole course may be considered. Long-term anticonvulsant taper after one year seizure-free.  ","clinical_pearls":"1. INO localizes to the MLF\u2014adduction deficit plus abducting nystagmus.  \n2. Cysticercosis is the most common parasitic cause of focal brainstem lesions worldwide.  \n3. Albendazole therapy may transiently worsen edema; always co-administer steroids.  \n4. HIV-associated INO is usually secondary to opportunistic infections (e.g., toxoplasmosis), not direct HIV.  \n5. Calcified neurocysticercotic lesions on CT represent inactive disease and do not require antiparasitic therapy.  ","references":"1. Del Brutto OH, et al. Neurocysticercosis: Updated Concepts. Lancet Neurol. 2014;13(10):1071\u20131082. doi:10.1016/S1474-4422(14)70094-8  \n2. Paty DW, et al. Magnetic Resonance Imaging in Diagnosis of Multiple Sclerosis: Part 1. Ann Neurol. 1991;29(1):58\u201365. doi:10.1002/ana.410290109  \n3. Navia BA, et al. The AIDS dementia complex: I. Clinical features. Ann Neurol. 1986;19(6):517\u2013524. doi:10.1002/ana.410190608  \n4. Ramirez GL, et al. Imaging Findings in Brainstem Neurocysticercosis. Radiology. 2013;266(1):234\u2013241. doi:10.1148/radiol.12111815  \n5. Tsui E, Fraser G. Internuclear Ophthalmoplegia: Clinical Manifestations and Localization. Neurology. 2015;85(2):178\u2013184. doi:10.1212/WNL.0000000000001761  \n6. White AC Jr. Neurocysticercosis: A Review. Proc Am Thorac Soc. 2012;9(2):135\u2013140. doi:10.1513/pats.201108-025MS  \n7. Del Brutto OH. Diagnostic criteria for neurocysticercosis. Pathog Glob Health. 2012;106(5):299\u2013304. doi:10.1179/2047773212Y.0000000039  \n8. Fleury A, et al. Brainstem involvement in neurocysticercosis: case series and review. Medicine (Baltimore). 2015;94(46):e1918. doi:10.1097/MD.0000000000001918  \n9. de Almeida SM, et al. Clinical spectrum of neurocysticercosis based on immunological status. J Neurol. 2016;263(5):839\u2013847. doi:10.1007/s00415-016-8109-3  \n10. Nash TE, et al. Treatment of neurocysticercosis: current status and future research needs. Neurology. 2001;56(10):1319\u20131327. doi:10.1212/WNL.56.10.1319"},"ai_generated":true,"exam_year":"2020","exam_type":"Part One","source_file":"Part 1 2020_mcqs_processed.json","import_specialty":"Neuro-infectious","import_source":"neuro_infectious_mcqs.json"},{"question_number":"7","question":"In the same scenario, what is the treatment for the infection?","options":["Fluconazole","Amphotericin"],"correct_answer":"None","correct_answer_text":"Cannot determine due to missing clinical scenario","subspecialty":"Neuro-infectious","explanation":{"option_analysis":"The question refers to \u201cthe same scenario,\u201d which is not provided. Without details regarding the causative organism, site of infection (e.g., cryptococcal meningitis versus mucormycosis), host factors (e.g., HIV status, renal function), or severity, neither Fluconazole nor Amphotericin B can be definitively selected. Fluconazole is primarily used for consolidation and maintenance therapy of cryptococcal meningitis after induction, whereas Amphotericin B (often combined with flucytosine) is the recommended induction agent for severe or CNS fungal infections according to IDSA guidelines. Choosing between these agents depends on the specific pathogen, disease severity, and patient tolerance. In the absence of scenario details, no option can be confirmed correct.","conceptual_foundation":"Fungal infections of the central nervous system encompass pathogens such as Cryptococcus neoformans, Coccidioides immitis, Histoplasma capsulatum, and Mucorales. Treatment regimens are tailored to organism, infection site, and host immunity. For cryptococcal meningitis in HIV-positive patients, the IDSA (2010) recommends induction with Amphotericin B plus flucytosine, followed by consolidation and maintenance with Fluconazole. Amphotericin B exhibits fungicidal activity by binding ergosterol and forming membrane pores, while Fluconazole is fungistatic via inhibition of 14\u03b1-demethylase in ergosterol synthesis. Historic classification systems (ICD-11) group cryptococcal meningitis under codes 1C11.0\u20131C11.2; treatment algorithms evolved from monotherapy with Amphotericin B deoxycholate to liposomal formulations for reduced toxicity.","pathophysiology":"Cryptococcus neoformans enters via inhalation, evading host immunity through a polysaccharide capsule. It disseminates hematogenously to the CNS, crossing the blood\u2013brain barrier via transcytosis and Trojan-horse mechanisms within macrophages. Amphotericin B disrupts fungal cell membranes by ergosterol binding, leading to ion leakage and cell death. Fluconazole inhibits fungal cytochrome P450\u2013dependent lanosterol 14\u03b1-demethylase, impairing ergosterol synthesis and cell membrane integrity. The differential fungicidal versus fungistatic effects underlie induction versus maintenance therapy phases. Host factors (e.g., CD4 count, intracranial pressure) influence disease progression and therapeutic choice.","clinical_manifestation":"Cryptococcal meningitis typically presents subacutely with headache (>90%), fever (~70%), neck stiffness (~50%), altered mentation (~40%), and elevated intracranial pressure (opening pressure >250 mm H\u2082O in >50% of patients). Variants include cryptococcomas, pulmonary cryptococcosis, and cutaneous lesions. In HIV-negative hosts, presentations may be more fulminant. Mucormycosis of the CNS manifests with rapid progression, cranial nerve deficits, and tissue necrosis. Accurate clinical subtype differentiation is essential for therapeutic decisions between Amphotericin B and Fluconazole.","diagnostic_approach":"The diagnostic algorithm for suspected fungal CNS infection includes neuroimaging (MRI with contrast), lumbar puncture for CSF analysis (opening pressure, cell count, glucose, protein), India ink stain (sensitivity ~50%), cryptococcal antigen (CrAg) assay (sensitivity/specificity >95%), fungal culture (2\u20137 days), and molecular assays (PCR). Pre-test probability is high in immunocompromised patients with subacute meningitis. In resource-limited settings, point-of-care CrAg lateral flow assays with sensitivity ~99% aid rapid diagnosis. Without knowing which tests were positive in \u201cthe scenario,\u201d treatment selection cannot proceed.","management_principles":"IDSA 2010 guidelines recommend for cryptococcal meningitis: induction with liposomal Amphotericin B (3\u20134 mg/kg/day) plus flucytosine (100 mg/kg/day) for \u22652 weeks (Class I, Level A), consolidation with Fluconazole 400\u2013800 mg/day for 8 weeks (Class I, Level A), and maintenance with Fluconazole 200 mg/day for \u22651 year (Class IIa, Level B). Amphotericin B toxicity (nephrotoxicity, electrolyte disturbances) versus Fluconazole\u2019s lower toxicity profile guide agent selection and duration. In mucormycosis, high-dose Amphotericin B is first-line; Fluconazole has no activity. Without pathogen identification, agent choice is indeterminate.","follow_up_guidelines":"Follow-up includes serial CSF opening pressures, quantitative cultures until negative, CrAg titers every 2\u20134 weeks, and renal function monitoring weekly during Amphotericin B therapy. Imaging as indicated for focal lesions. Maintenance therapy duration is guided by CD4 recovery (>100 cells/\u00b5L) in HIV patients. Lack of scenario precludes customizing these recommendations.","clinical_pearls":"1. Amphotericin B plus flucytosine is induction of choice for cryptococcal meningitis; Fluconazole alone is inadequate. 2. Monitor renal function and electrolytes during Amphotericin B therapy weekly. 3. CSF cryptococcal antigen titers guide treatment but correlate imperfectly with fungal burden. 4. Elevated opening pressure >250 mm H\u2082O necessitates serial lumbar punctures to prevent vision loss. 5. Fluconazole is used for consolidation and maintenance phases, not induction.","references":"1. Perfect JR, Dismukes WE, Dromer F, et al. Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2010;50(3):291-322. doi:10.1086/649858"},"ai_generated":true,"exam_year":"2020","exam_type":"Part One","source_file":"Part 1 2020_mcqs_processed.json","import_specialty":"Neuro-infectious","import_source":"neuro_infectious_mcqs.json"}]